Fluxit Tablet: Each tablet contains Flupentixol Dihydrochloride BP 0.584 mg equivalent to Flupentixol 0.5 mg and Melitracen Hydrochloride INN 11.25 mg equivalent to Melitracen 10 mg.
Fluxit consists of two well-known and well-proven compounds; Flupentixol-a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and Melitracen-a bipolar thymoleptic with activating properties in low doses. In combination the compounds render a preparation with antidepressant, anxiolytic and activating properties.
Mode of action:
Flupentixol performs anxiolytic effects by blocking dopamine receptors especially receptors. Melitracen, a tricyclic antidepressant (TCA), inhibits norepinephrine and serotonin reuptake.
Pharmacokinetics:
Maximal serum concentration is reached in about 4 hours after oral administration of flupentixol and about 4 hours after oral administration of melitracen. The biological half-life of flupentixol is about 35 hours and that of melitracen is about 19 hours. The combination of flupentixol and melitracen does not seem to influence the pharmacokinetic properties of the individual compounds.
Anxiety, depression, asthenia, psychogenic depression, depressive neuroses, masked depression, long lasting myogenic headache, migraine, gastrointestinal disturbances without organic findings, psychosomatic affections accompanied by anxiety and apathy, menopausal depression, dysphoria and depression in alcoholics and drug-addicts.
Adults: Usually 2 tablets daily (morning and noon). In severe cases the morning dose may be increased to 2 tablets. Elderly: 1 tablet in the morning. Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness, additional treatment with sedative in the acute phase is recommended.
Fluxit may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO-inhibitors may cause hypertensive crisis. Neuroleptics and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.
Overdosage: Symptoms: In cases of overdosage the symptoms of intoxications by melitracen, especially of anticholinergic nature, dominate. More rarely extrapyramidal symptoms due to flupentixol occur.
& lacation: Fluxit should preferably not be given during pregnancy and lactation.
If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.
Store in a cool and dry place, protected from light.